SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading
A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...
American Association of Individual Investors1d
Which Is a Better Investment, ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. Stock?
Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
Saniona AB: Saniona Appoints Pierandrea Muglia, M.D., as Chief Medical Officer
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experie ...
Morgan Stanley Reaffirms Equal Weight Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They ...
ABC 10News San Diego3d
Ex-San Diego pharma VP pleads guilty to securities fraud for insider trading
George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the company's products ...
Former San Diego Pharma VP pleads guilty to securities fraud for insider trading
George Demos admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the ...
Acadia Pharmaceuticals assumed with an Equal Weight at Morgan Stanley
Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent ...
Le Lézard6d
Clinical Data from Open-Label DAFFODILtm Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Acadia Pharmaceuticals Inc. today announced that the journal Med published results from the open-label study, DAFFODILtm, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® ...
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised)
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December ...
ACADIA Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Full Year 2024 Results Key Financial Results Revenue: US$957.8m (up 32% from ...
Acadia Pharmaceuticals, Saniona announce results from ACP-711 cohorts
Acadia Pharmaceuticals (ACAD) and Saniona announced the completion of the two originally planned cohorts in their Phase 1 ...
Le Lézard8d
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
Acadia Pharmaceuticals Inc. and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: ...